Related Experiment Videos
Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality
Chia C Chuang1, Shan T Wang, Wen C Chen
1Department of Emergency Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Abstract:
This prospective study aimed to delineate the association between the serum levels of macrophage migration inhibitory factor (MIF) and the risks of early mortality in 112 patients who presented with clinically severe sepsis. Previous studies showed that elevated serum MIF levels on the first day are associated with an increased risk of 28-day mortality. Nonsurvivors may be the sickest population on arrival. Not all patients with severe sepsis follow the same clinical pathway, however, and the sequential change in MIF might be an important predictor of mortality. We hypothesized that, for septic patients, in addition to serum MIF levels on day 1, the percentage of change in MIF between days 1 and 2 after arriving in the emergency department predicts the probability of early mortality. Serum MIF levels were measured on days 1 (emergency department arrival) and 2 (24 h after arrival). Patients with a high percentage of increase between MIF levels on days 1 and 2 had higher 3-day (odds ratio, 1.8; 95% confidence interval, 1.2-2.6; P = 0.003) and 7-day mortalities (odds ratio, 1.4; 95% confidence interval, 1.0-1.9; P = 0.03) after adjusting for age and day-1 serum MIF levels. In conclusion, an increase in serum MIF from the first to second day of admission in patients with severe sepsis indicates a higher risk of early mortality; therefore, these patients need more aggressive therapeutic intervention.
Insights
Rising serum macrophage migration inhibitory factor (MIF) levels in severe sepsis patients from day 1 to day 2 predict higher early mortality. This indicates a need for aggressive treatment in these critically ill individuals.
Area of Science:
- Biomedical research
- Clinical immunology
- Critical care medicine
Background:
- Elevated serum macrophage migration inhibitory factor (MIF) on day 1 of severe sepsis is linked to increased 28-day mortality.
- Patient clinical pathways in severe sepsis vary, suggesting sequential biomarker changes are crucial for predicting outcomes.
- The dynamic change in MIF levels may offer a more nuanced understanding of mortality risk than static measurements.
Purpose of the Study:
- To investigate the association between the percentage change in serum MIF levels from day 1 to day 2 and early mortality in severe sepsis patients.
- To determine if the sequential change in MIF predicts mortality independently of initial MIF levels and patient age.
- To identify patients with severe sepsis who may benefit from intensified therapeutic interventions based on MIF level dynamics.
Main Methods:
- Prospective study involving 112 patients with clinically severe sepsis.
- Serum MIF levels were measured on day 1 (emergency department arrival) and day 2 (24 hours post-arrival).
- Statistical analysis, including logistic regression, was used to assess the relationship between MIF change and 3-day and 7-day mortality, adjusting for covariates.
Main Results:
- A significant percentage increase in serum MIF from day 1 to day 2 was associated with higher 3-day mortality (OR, 1.8; 95% CI, 1.2-2.6; P = 0.003).
- This increase in MIF also correlated with elevated 7-day mortality (OR, 1.4; 95% CI, 1.0-1.9; P = 0.03), even after adjusting for day-1 MIF levels and age.
- These findings highlight the predictive value of MIF level dynamics in severe sepsis.
Conclusions:
- An increasing trend in serum MIF levels during the initial 24 hours of hospitalization for severe sepsis signifies an elevated risk of early death.
- Patients exhibiting this MIF pattern require prompt and aggressive medical management.
- Monitoring sequential MIF levels can aid in risk stratification and guide therapeutic strategies in severe sepsis management.